International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8331037
Original Article
Clinical Profile of Dengue Fever In Children: A Hospital-Based Study
 ,
Published
Aug. 31, 2023
Abstract

Background: Dengue is a mosquito-borne arboviral disease that has become a global public health challenge, causing epidemics in tropical and sub-tropical countries during the rainy season. This study aimed to assess the clinical profile of dengue infection in children under 12 years of age and to evaluate the outcome of dengue fever.

Methods: The prospective observational study was conducted at Kanyakumari medical college on children with dengue fever admitted from 2020 to 2021. Demographics, clinical profiles, and outcomes of the children with dengue fever were studied. Based on the severity of the disease, children were categorized into three groups; group A has dengue fever. Group B; has dengue fever with warning signs, and group C; has severe dengue.

Results: A total of 63 children were enrolled in the study, with a male predominance (54%) and a highly affected age group of >8 years (65.1%). Fever, vomiting, and abdominal pain were the most common presenting complaints in children. Hepatomegaly was the most common clinical finding .Pleural effusion was reported in 5 children from group B and four children from group C, with significant differences based on the severity of dengue. Most children required 8-10 days of hospitalization, and treatment of antipyretic and intravenous fluids was majorly used. All children recovered from dengue with no mortality.

Conclusion: Early recognition of danger signs clinically and appropriate treatment can reduce mortality and improve patient outcome.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
353 Views
312 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved